Looking at the results of the early trials presented at the 2018 American Society of Clinical Oncology (ASCO) conference can help identify the molecules and strategies that will potentially enter the practices of tomorrow. It is in this spirit that this subject has justified the attention of residents in oncology and the writing of this synthesis. Molecules that can represent breakthrough innovations are presented as well as new therapeutics under development acting on targets already validated in clinical practice and early data of checkpoint inhibitors in combination with different immunomodulators, as well as new strategies for immunotherapies (vaccines and cell therapy).
Keywords: Combinaison; Combination; Early clinical trials; Essai clinique phase précoce; First-in-class; First-in-man; Innovation; Médecine personnalisée; Personalized medicine; Phase 1.
Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.